UNSPSC 51283205: Oleandomycin

This classification denotes a macrolide antibiotic with the molecular formula C35H61NO12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P8ZQ646136, chemically known as 12-((2,6-didesoxy-3-o-methyl-alpha-k-arabino-hexopyranosyl)oxy)-8-hydroxy-5,7,8,11,13,15-hexamethyl-14-((3,4,6-tridesoxy-3-dimethylamino-beta-d-xylo-hexopyranosyl)oxy)-1,9-dioxaspiro(2.13)hexadecan-4,10-dion but generally known as oleandomycin, which bears US NIH Compound Identifier 19822.

UNSPSC 51283205 Oleandomycin is a Commodity code that nominally designates a specific antibiotic pharmaceutical, but recent state and local solicitation activity under this code does not reflect purchases of oleandomycin itself. Instead, the code tags a broader set of pharmaceutical and medical supply procurements—including naloxone (an opioid antagonist), generic multi-source pharmaceuticals, over-the-counter products, and emergency medical supplies—suggesting a mismatch between the code's nominal scope and the actual buying patterns it captures in state and local procurement systems. State and local issuing bodies using this code include county health departments, municipal fire departments, state health agencies, and cooperative purchasing alliances. The work being solicited ranges from emergency-response medications and drug-deactivation systems to comprehensive pharmacy benefit program design and generic pharmaceutical supply contracts with authorized wholesalers.

Recent activity appears across Florida, Texas, Minnesota, and Oregon through four representative solicitations: Seminole County, Florida posted an IFB on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023, response deadline; the City of Tampa issued an IFB for 169 line items of medical and first aid supplies for its Fire Department Rescue Division, with a March 13, 2026, deadline and an estimated contract value of $700,000.00, designated as a sheltered market opportunity for certified Small Local Business Enterprises with a 5 percent bid discount; the Texas Health and Human Services Commission posted an RFI on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon through authorized wholesalers including AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC. The code shows no coherent concentration but rather scattered activity in emergency medical supply procurement and pharmacy benefit program management.